Redeye updates its estimates and valuation following OEM releasing its Q1 2025 report. While Q1 figures slightly underperformed our projections, we judge OEM will continue to execute on organic and acquired growth opportunities despite myriad economic uncertainties. Encouragingly, OEM announced an M&A deal in late April 2025.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/